REPH - Recro Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5223.59M
Enterprise Value 3271.06M
Trailing P/E N/A
Forward P/E 134.76
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)2.70
Price/Book (mrq)N/A
Enterprise Value/Revenue 33.27
Enterprise Value/EBITDA 6-6.56

Trading Information

Stock Price History

Beta (3Y Monthly) 0.58
52-Week Change 383.46%
S&P500 52-Week Change 36.69%
52 Week High 310.69
52 Week Low 35.07
50-Day Moving Average 39.72
200-Day Moving Average 38.71

Share Statistics

Avg Vol (3 month) 3240.46k
Avg Vol (10 day) 3166.67k
Shares Outstanding 5N/A
Float 16.11M
% Held by Insiders 16.09%
% Held by Institutions 170.09%
Shares Short (Jun 28, 2019) 4687.63k
Short Ratio (Jun 28, 2019) 42.94
Short % of Float (Jun 28, 2019) 43.65%
Short % of Shares Outstanding (Jun 28, 2019) 43.10%
Shares Short (prior month May 31, 2019) 4730.9k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin -83.56%
Operating Margin (ttm)-59.62%

Management Effectiveness

Return on Assets (ttm)-17.18%
Return on Equity (ttm)-2,496.22%

Income Statement

Revenue (ttm)82.87M
Revenue Per Share (ttm)3.92
Quarterly Revenue Growth (yoy)28.30%
Gross Profit (ttm)-5.8M
EBITDA -41.34M
Net Income Avi to Common (ttm)-69.25M
Diluted EPS (ttm)-3.29
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)58.02M
Total Cash Per Share (mrq)2.62
Total Debt (mrq)107.71M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)3.57
Book Value Per Share (mrq)-0.86

Cash Flow Statement

Operating Cash Flow (ttm)-40.8M
Levered Free Cash Flow (ttm)-60.23M